| Drug Name | XELJANZ (tofacitinib) |
|---|---|
| Drug Class |
Immunosuppressant
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Rheumatology
|
| Risk |
Important Drug Warning - Risk of Major Adverse Cardiovascular Events and Malignancies (Excluding NMSC) with Use of Xeljanz/Xeljanz XR (tofacitinib) Relative to TNFi Therapy |
| Dear Healthcare provider letter DHPC |
|